Banci, L, Bertini, I, Boca, M, Girotto, S, Martinelli, M, Valentine, JS, and Vieru, M (2008).
SOD1 and Amyotrophic Lateral Sclerosis: Mutations and Oligomerization
PLoS One 3(2).

Ferri, A, Nencini, M, Cozzolino, M, Carrara, P, Moreno, S, and Carri, MT (2008).
Inflammatory cytokines increase mitochondrial damage in motoneuronal cells expressing mutant SOD1
Neurobiology of Disease.

Ito, H, Wate, R, Zhang, J, Ohnishi, S, Kaneko, S, Ito, H, Nakano, S, and Kusaka, H (2008).
Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice
Experimental Neurology 213:448-455.

Mali, Y and Zisapels, N (2008).
Gain of Interaction of ALS-linked G93A Superoxide Dismutase with Cytosolic Malate Dehydrogenase
Neurobiology of Disease 32:133-141.

Mulligan, VK, Kerman, A, Ho, S, and Chakrabartty, A (2008).
Denaturational Stress Induces Formation of Zinc-Deficient Monomers of Cu,Zn Superoxide Dismutase: Implications for Pathogenesis in Amyotrophic Lateral Sclerosis
Journal of Molecular Biology(383):424-436.

Secondo, A, De Mizio, M, Zirpoli, L, Santillo, M, and Mondola, P (2008).
The Cu-Zn superoxide dismutase (SOD1) inhibits ERK phosphorylation by muscarinic receptor modulation in rat pituitary GH3 cells
Biochemical and Biophysical Research Communications 376:143-147.

Teh, A, Kanamasa, S, Kajiwara, S, and Kumasaka, T (2008).
Structure of Cu/Zn superoxide dismutase from the heavy-metal-tolerant yeast Cryptococcus liquefaciens strain N6
Biochemical and Biophysical Research Communications(374):475-478.

Banci, L, Bertini, I, D'Amelio, N, Libralesso, E, Turano, P, and Valentine, JS (2007).
Metalation of the Amyotrophic Lateral Sclerosis Mutant Glycine 37 to Arginine Superoxide Dismutase (SOD1) Apoprotein Restores its Structural and Dynamical Properties in Solution to those of Metalated Wild-Type SOD1
Biochemistry 46:9953-9962.

Bryant, C (2007).
Take Two Drops of Lizard Spit and Call Me in the Morning: Gila Monster Protein Treats Diabetes, Researchers Look for Other Applications
Webpublished.

Chen, Z (2007).
C-Terminal Modification Is Required for GABARAP-Mediated GABAA Receptor Trafficking
JNEUROSCI.

Chen, Z (2007).
C-Terminal Modification Is Required for GABARAP-Mediated GABAA Receptor Trafficking
JNEUROSCI.

Chu, Y and Kordower, J (2007).
Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
Neurobiology of Disease 25:134-149.

Dali-Youcef, N, Lagouge, M, Froelich, S, Koehl, C, Schoonjans, K, and Auwerx, J (2007).
Sirtuins: The 'magnificent seven', function, metabiolism and longevity
Annals of Medicine 39(5):335-345.

Egido-Gabas, M, Canals, D, Casas, J, Llebaria, A, and Delgado, A (2007).
Aminocyclitols as pharmacological chaperones for glucocerebrosidase, a defective enzyme in Gaucher disease
Chem Med Chem 2(7):992-994.

Egido-Gabas, M, Canals, D, Casas, J, Llebaria, A, and Delgado, A (2007).
Aminocyclitols as pharmacological chaperones for glucocerebrosidase, a defective enzyme in Gaucher disease
Chem Med Chem 2(7):992-994.

Guillon, C, Koppel, G, Brownstein, M, Chaney, M, and ea (2007).
Azetidinones as vasopressin V1a antagonists
Bioorg Med Chem 15 (5):2054-2080.

Ishigaki, T, Ohki, I, Oyama, T, Machida, S, Morikawa, K, and Tate, S (2007).
Purification, crystallization and preliminary X-ray analysis of the ligand-binding domain of human lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1)
NIH PUBMED.

Kitani, K, Oguma, S, Nishiki, T, Ohmori, I, Galons, H, Matsui, H, Meijer, L, and Tomizawa, K (2007).
A Cdk5 Inhibitor Enhances Induction of Insulin Secretion by Exendin-4 Both in Vitro and in Vivo.
J Physiol Sci. 57(4).

Matsunaga, S, Xie, Q, Kumano, M, Niimi, S, Sekizawa, K, Sakakibara, Y, Komba, S, and Machida, S (2007).
Lectin-like oxidized low-density lipoprotein receptor (LOX-1) functions as an oligomer and oligomerization is dependent on receptor density.
Exp Cell Res. 313(6):1203-14.

McEachern, KA, Fung, J, Komarnitsky, S, Siegel, CS, Chuang, W, Hutto, E, Shayman, JA, Grabowski, GA, Aerts, JMFG, Cheng, SH, Copeland, DP, and Marshall, J (2007).
A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease
Molecular Genetics and Metabolism 91(3):259-267.

McEachern, KA, Fung, J, Komarnitsky, S, Siegel, CS, Chuang, W, Hutto, E, Shayman, JA, Grabowski, GA, Aerts, JMFG, Cheng, SH, Copeland, DP, and Marshall, J (2007).
A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease
Molecular Genetics and Metabolism 91(3):259-267.

Nelson, P, Poon, T, Guan, X, Schnabel, C, Wintle, M, and Fineman, M (2007).
The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes.
Diabetes Technol Ther. 9(4):317-26.

Saeed, S, Shad, K, Saleem, T, Javed, F, and Khan, M (2007).
Some new prospects in the understanding of the molecular basis of the pathogenesis of stroke
Experimental Brain Research 182(1):1-10.

Stasser, JP, Siluvai, GS, Barry, AN, and Blackburn, NJ (2007).
A Multinuclear Copper (I) Cluster Forms the Dimerization Interface in Copper-Loaded Human Copper Chaperone for Superoxide Dismutase
Biochemistry(46):11845-11856.

Viswanathan, P, Chaudhuri, A, Bhatia, R, Al-Atrash, F, Mohanty, P, and Dandona, P (2007).
Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin.
Endocr Pract. 13(5):444-50.